Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cardiovascular, aging
- Who it enrolls
- age 45 Years to 55 Years; female; healthy volunteers accepted; no BMI minimum stated; conditions: Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular
- Interventions
- Metformin; semaglutide; Anti-hypertensives; Lipid Lowering Medication; Life style intervention; Fezolinetant; Hormonal therapy
- Conditions
- Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular
- Phase and size
- Phase 2, Phase 3 · 200 participants
- Dates
- Start 2026-03-01
Primary completion 2029-10-31 - Sponsor
- University of Colorado, Denver (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Epigenetic aging measurements of "PhenoAge"Up to 2 years
- Epigenetic aging measurements of "GrimAge"Up to 2 years
02Eligibility
Who can take part
Inclusion Criteria: * aged 45-55 * In the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18 * No current use of hormone therapy or hormonal contraception * Presence of a uterus and at least one ovary in order to track menstrual patterns * Have a smartphone and broadband access adequate to accept telehealth appointments Exclusion Criteria: * Lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth) * Lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant. * Pregnancy or actively trying to get pregnant * Inability to adhere to study protocol schedule * Untreated alcoholism * Un- Diagnosed abnormal uterine bleeding * Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN 2) for participants with a BMI\> 30 kg/m2.
03Change log
Registry changes
No changes recorded since the trial was added.